Polymer-Drug Conjugates for Anticancer Drug Delivery.

Area of Science:

• Biomaterials Science
• Drug Delivery Systems
• Oncology

Background:

• Polymer-drug conjugates (PDCs) involve covalently linking drugs to polymers, forming advanced drug delivery systems.
• Current research focuses on PDCs for cancer therapy, with several candidates in clinical trials.
• PDCs demonstrate potential for enhanced tumor targeting, improved therapeutic index, and sustained drug release.

Purpose of the Study:

• To review critical design aspects of polymer-drug conjugates for cancer drug delivery.
• To highlight the importance of polymer, drug, linkage, and targeting group selection in PDC effectiveness.
• To discuss the influence of functionalization on in vivo behavior and the necessity of safety evaluations.

Main Methods:

• Review of existing literature on polymer-drug conjugate synthesis and application in cancer therapy.
• Analysis of factors influencing PDC performance, including drug release kinetics and tumor accumulation.
• Examination of cell uptake mechanisms and their role in overcoming multi-drug resistance.

Main Results:

• PDCs exhibit enhanced tumor accumulation, increased therapeutic index, and prolonged circulation times.
• Sustained drug release profiles are achievable through controlled conjugation and polymer design.
• PDCs show reduced sensitivity to efflux pumps, mitigating multi-drug resistance.

Conclusions:

• The effectiveness of PDCs hinges on careful selection of polymer, drug, linkage, and targeting strategies.
• Functionalization allows for controlled drug release and multi-functionality, enhancing versatility.
• Ongoing clinical trials underscore the therapeutic promise of PDCs in cancer treatment, necessitating thorough safety and efficacy assessments.